Celgene Pays $280M in Off-Label Marketing FCA Case

Celgene has agreed to pay $280 million to settle allegations that the company marketed two of its drugs for off-label uses.  According to DOJ:

The settlement resolves allegations brought in a “whistleblower” lawsuit that Celgene promoted two cancer drugs – Thalomid and Revlimid – for uses that were not approved by the FDA and not covered by federal health care programs. The allegations included the use of false and misleading statements about the drugs, and paying kickbacks to physicians to induce them to prescribe the drugs.

The whistleblower will receive a portion of the settlement as a reward for bringing the allegations to the government’s attention.

Read the DOJ press release here.